Pulmonology

H-CYTE Raises $6 Million to Accelerate FDA Approval Process of Next Generation Cellular Therapy for COPD

Monday, November 18, 2019 - 1:00pm

The new funding will be used to advance the companys development of industry-leading medical treatments for chronic lung diseases such as COPD.

Key Points: 
  • The new funding will be used to advance the companys development of industry-leading medical treatments for chronic lung diseases such as COPD.
  • It is estimated that 24 million people in the U.S. have COPD, an umbrella term that encompasses many other conditions, including emphysema and chronic bronchitis.
  • According to the CDC , more than 140,000 Americans die from this condition each year and there is currently no cure.
  • H-CYTE recently entered into a long-term agreement with Rion that will enable H-CYTE to develop proprietary biologics for treatment of COPD.

Translate Bio to Present at Upcoming Investor Conferences

Wednesday, November 13, 2019 - 12:30pm

A replay of the webcast will be archived on the Translate Bios website for 30 days following the presentation.

Key Points: 
  • A replay of the webcast will be archived on the Translate Bios website for 30 days following the presentation.
  • Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
  • Translate Bio is primarily focused on applying its MRT platform to treat pulmonary diseases caused by insufficient protein production or where production of proteins can modify disease.
  • Translate Bios lead program is being developed as a treatment for cystic fibrosis (CF) and is in an ongoing Phase 1/2 clinical trial.

Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

Tuesday, November 12, 2019 - 9:01pm

Conference call and webcast to be held today at 4:30 p.m. Eastern Time

Key Points: 
  • Conference call and webcast to be held today at 4:30 p.m. Eastern Time
    YARDLEY, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September30, 2019, and provided recent operational highlights.
  • The number of XHANCE (fluticasone propionate) prescriptions increased by 27% from second quarter to third quarter 2019 and by 18% from September to October 2019.
  • The Company generated $8.7 million and $19.3 million of XHANCE net revenue during the three-month and nine-month periods ended September30, 2019.
  • Selling, general and administrative expenses were $25.3 million and $77.6 million during the three-month and nine-month periods ended September30, 2019.

PulmOne Now Offering FeNO by NIOX® with Its MiniBox+™ Complete Pulmonary Function Testing System

Thursday, November 7, 2019 - 2:00pm

The MiniBox+, a desktop, cabinless device, is used by specialists and primary care physicians for complete Pulmonary Function Testing (PFT) of their patients, as recommended by the American Thoracic Society (ATS).

Key Points: 
  • The MiniBox+, a desktop, cabinless device, is used by specialists and primary care physicians for complete Pulmonary Function Testing (PFT) of their patients, as recommended by the American Thoracic Society (ATS).
  • Integrating the NIOX VERO asthma management system expands the testing capabilities of the MiniBox+, enabling physicians to detect and treat an even wider range of respiratory disorders.
  • "We are delighted to offer our customers the world's leading FeNO system as a new enhancement to the MiniBox+.
  • NIOX VERO cannot be used with infants or by children under the age of 7, as measurement requires patient cooperation.

Green Park Collaborative and Allergy & Asthma Network Launch coreASTHMA to Develop Consensus on Critical Outcomes in Moderate to Severe Asthma Clinical Research

Tuesday, October 15, 2019 - 3:13pm

This initiative, coreASTHMA, will engage patients, clinicians, regulators, payers, health technology assessors, product developers, and other key stakeholders in a structured consensus process to develop the core outcome set.

Key Points: 
  • This initiative, coreASTHMA, will engage patients, clinicians, regulators, payers, health technology assessors, product developers, and other key stakeholders in a structured consensus process to develop the core outcome set.
  • Asthma is a disease of chronic airway inflammation, with symptoms such as coughing, wheezing and shortness of breath impacting patients' daily functioning and quality of life.
  • Despite multiple treatment options for management of asthma, many patients with severe or poorly controlled asthma fail to improve with existing treatments.
  • "At this critical juncture, we want to ensure the patient voice translates to asthma research and policy decisions," said Tonya Winders, CEO of AAN.

Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019

Tuesday, October 15, 2019 - 7:00am

LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (COPD) at CHEST Annual Meeting (CHEST) on Monday, October 21, 2019 at 02:30 AM CDT.

Key Points: 
  • LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (COPD) at CHEST Annual Meeting (CHEST) on Monday, October 21, 2019 at 02:30 AM CDT.
  • Kathleen Rickard, M.D., CMO at Verona Pharma, will expand on symptom data first announced by the Company on March 26, 2018 where ensifentrine produced clinically and statistically significant improvements in lung function as well as significant and progressive improvements in COPD symptoms.
  • Oral Presentation/Poster: Poster E1037 Unique dual phosphodiesterase 3/4 inhibitor, ensifentrine, significantly improves COPD symptoms including dyspnea
    COPD is a progressive and life-threatening respiratory disease without a cure.
  • Nebulized ensifentrine (RPL554) has shown significant and clinically meaningful improvements in both lung function and COPD symptoms, including breathlessness, in Verona Pharmas prior Phase 2 clinical studies in patients with moderate-to-severe COPD.

VIDA Partners With TeraRecon, Inc. For Distribution Of AI-Powered Lung Analysis

Monday, October 14, 2019 - 6:00pm

CORALVILLE, Iowa, Oct. 14, 2019 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, announced a distribution agreement with TeraRecon, Inc., a leader in advanced visualization, artificial intelligence, image viewing, and post-processing.

Key Points: 
  • CORALVILLE, Iowa, Oct. 14, 2019 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, announced a distribution agreement with TeraRecon, Inc., a leader in advanced visualization, artificial intelligence, image viewing, and post-processing.
  • By precisely quantifying lung characteristics in a chest CT scan, LungPrint helps providers detect COPD and other interstitial lung disease earlier, often when debilitating symptoms have yet to occur.
  • Early detection of chronic lung disease is reported to elongate life expectancies and reduce overall healthcare costs ( Larsson, et.
  • VIDA's LungPrint solution aims to provide greater precision and personalization across a range of lung diseases including lung cancer, obstructive airway diseases like emphysema and asthma, and interstitial lung disease.

Identification of COPD, asthma and overlap syndrome can be teased out with spirometry following use of bronchodilator

Monday, October 14, 2019 - 1:23pm

Spirometry with BD testing is recommended but not routinely utilized in clinical practice to diagnose COPD.

Key Points: 
  • Spirometry with BD testing is recommended but not routinely utilized in clinical practice to diagnose COPD.
  • BD testing will also aid physicians in identifying subjects with possible asthma and ACOS.
  • Differentiating COPD from overlap syndrome is of clinical importance, owing to differences in clinical management and outcomes.
  • The researchers wrote: "Routine underutilization of spirometry with BD testing may lead to overdiagnose 39% of subjects as having COPD.

Aclidinium is safe and reduces COPD flare-ups, regardless of recent exacerbations

Monday, October 14, 2019 - 1:23pm

Second, although aclidinium has been shown to be a good bronchodilator, the overall study indicates that it is also effective in reducing exacerbations, which is a pivotal finding.

Key Points: 
  • Second, although aclidinium has been shown to be a good bronchodilator, the overall study indicates that it is also effective in reducing exacerbations, which is a pivotal finding.
  • Most studies of exacerbations include only patients who have had an exacerbation in the preceding year whereas ASCENT included patients both with and without exacerbations.
  • "Prevention of exacerbations of COPD should be a treatment goal in COPD patients regardless of whether they have a history of recent exacerbations," concluded Dr.
  • In the highest risk patients, aclidinium bromide was superior to placebo in reducing exacerbations but did not increase cardiovascular events in high-risk patients.

bioAffinity Technologies Announces Members of its Scientific and Medical Advisory Board

Wednesday, October 2, 2019 - 4:00pm

Gerard Silvestri , MD, MS, FCCP, Professor of Medicine and Lung Cancer Pulmonologist at the Medical University of South Carolina.

Key Points: 
  • Gerard Silvestri , MD, MS, FCCP, Professor of Medicine and Lung Cancer Pulmonologist at the Medical University of South Carolina.
  • bioAffinity is currently conducting a test validation trial for CyPath Lung, a Laboratory Developed Test (LDT) for the diagnosis of early-stage lung cancer.
  • bioAffinity Technologies, Inc. ( www.bioaffinitytech.com ) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.
  • Research and optimization of its platform technology is conducted in bioAffinity Technologies laboratories at the University of Texas San Antonio (UTSA).